Biogen Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Great. Good morning, everybody. Thanks for joining us for the next session this morning. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. We're pleased to have Biogen with us this morning and Michel Vounatsos, the CEO; and Alisha Alaimo, who runs Commercial.
Quickly before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures. And I'm going to turn it over to Michel to make some opening comments, and then we'll get into Q&A.
Thank you, Matt, and good morning, everyone. Before I begin, I would like to state that we will be making some forward-looking statements, which contain risks and uncertainties, so I encourage everyone to go to the risk factors discussed in our SEC filing.
Before I
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
